CNS Pharmaceuticals CNSP 深 沪
等待开盘 04-02 09:30:00 美东时间
2.2754
-0.115
-4.79%
华盛通- 最 高2.68
- 今 开2.68
- 成交量 2.27万股
- 最 低 2.17
- 昨 收 2.39
- 总市值 141.14万
- 52周最高 34.7988
- 市盈率 静 --
- 换手率 3.65%
- 52周最低 2.0573
- 委 比 -63.29%
- 总股本 62.03万
- 历史最高 5121000.00
- 量 比 0.36
- 振 幅 21.34%
- 历史最低 2.0573
- 每 手 1
- 风险率 3.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CNS Pharmaceuticals Launches Global Search For Neurology And Oncology Assets, Shifts Focus From Glioblastoma
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation driven by a
03-11 20:42
CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline
CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline CNS Pharmaceuticals Inc. announced a corporate growth strategy to build a higher-value pipeline in neurology and oncology. The c
03-11 20:35
CNS Pharmaceuticals Appoints New Chief Medical Officer
CNS Pharmaceuticals ( ($CNSP) ) has provided an update. On February 26, 2026, C...
03-03 07:12
CNS Pharmaceuticals names Lynne Kelley chief medical officer
CNS Pharmaceuticals names Lynne Kelley chief medical officer CNS Pharmaceuticals Inc. appointed Lynne Kelley, MD, FACS, as Chief Medical Officer, completing its executive leadership team. Kelley brings more than 20 years of experience in clinical development, translational medicine and regulatory st
03-02 21:25
CNS Pharmaceuticals Appoints Steve O'Loughlin CFO, Effective March 2, Succeeding Christopher Downs
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001729427/000168316826001066/cns_8k.htm
02-17 21:42
CNS Pharmaceuticals Sets New Executive Compensation Agreements
CNS Pharmaceuticals Sets New Executive Compensation Agreements CNS Pharmaceuticals Inc. has appointed Steve O'Loughlin as Chief Financial Officer effective March 2, 2026, with an initial annual base salary of $450,000 and eligibility for an annual bonus targeted at 40% of base salary, as well as ann
02-17 21:36
CNS Pharmaceuticals Names New CEO and Executive Team
CNS Pharmaceuticals Names New CEO and Executive Team CNS Pharmaceuticals Inc. has announced new additions to its executive team, effective March 2, 2026. Rami Levin is the recently appointed President and CEO. Steven O'Loughlin will serve as Chief Financial Officer, Eric Faulkner as Chief Technology
02-17 21:25
CNS Pharmaceuticals Inc. Outlines Strategy to Sharpen Focus, Optimize Pipeline, and Align Capital Allocation for Long-Term Value Creation
CNS Pharmaceuticals Inc. Outlines Strategy to Sharpen Focus, Optimize Pipeline, and Align Capital Allocation for Long-Term Value Creation CNS Pharmaceuticals Inc. has announced a strategic plan focused on transforming its operations to create long-term value for shareholders. The newly appointed Pre
01-27 22:51
CNS Pharmaceuticals Announces New CEO Appointment
The latest announcement is out from CNS Pharmaceuticals ( ($CNSP) ). On Decembe...
2025-12-17 21:58
CNS Pharmaceuticals CEO John Climaco Steps Down, Rami Levin Named New Chief Executive
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous
2025-12-17 20:08
